Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paris polyphylla detoxification tincture is a traditional Chinese medicine (TCM) herbal preparation developed by the Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital. The primary active component is derived from the rhizome of *Paris polyphylla* (known as Chonglou in TCM), which contains a variety of steroidal saponins, including polyphyllin I, II, VI, and VII. These constituents exhibit anti-inflammatory, analgesic, and antiviral activities. In clinical practice, the tincture is used as an adjuvant treatment for acute herpes zoster (shingles) to promote the healing of skin lesions, alleviate acute pain, and reduce the incidence of postherpetic neuralgia (PHN). It is typically evaluated in real-world settings in combination with standard antiviral therapies like acyclovir or famciclovir.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Paris polyphylla detoxification tincture.